End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
28,000 KRW | +0.72% | +7.28% | +8.32% |
2023 | NeoPharm CO., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
2019 | NeoPharm CO., LTD. announced that it has received KRW 31.970667276 billion in funding | CI |
Sales 2024 * | 120B 87.84M | Sales 2025 * | 145B 106M | Capitalization | 219B 160M |
---|---|---|---|---|---|
Net income 2024 * | 23B 16.84M | Net income 2025 * | 30B 21.96M | EV / Sales 2024 * | 0.75 x |
Net cash position 2024 * | 128B 93.99M | Net cash position 2025 * | 152B 112M | EV / Sales 2025 * | 0.46 x |
P/E ratio 2024 * |
10
x | P/E ratio 2025 * |
7.63
x | Employees | 142 |
Yield 2024 * |
2.68% | Yield 2025 * |
2.68% | Free-Float | 56.96% |
1 day | +0.72% | ||
1 week | +7.28% | ||
Current month | +7.69% | ||
1 month | +8.53% | ||
3 months | +1.63% | ||
6 months | +24.17% | ||
Current year | +8.32% |
Managers | Title | Age | Since |
---|---|---|---|
Yang-Soo Kim
CEO | Chief Executive Officer | 54 | 12-07-31 |
Yoon Kim
CTO | Chief Tech/Sci/R&D Officer | 59 | 00-06-30 |
Woo-Jae Lim
BRD | Director/Board Member | 45 | 21-03-24 |
Members of the board | Title | Age | Since |
---|---|---|---|
Yoon Kim
CTO | Chief Tech/Sci/R&D Officer | 59 | 00-06-30 |
Dong-Jin Choi
BRD | Director/Board Member | 64 | 19-03-20 |
Yang-Soo Kim
CEO | Chief Executive Officer | 54 | 12-07-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 28,000 | +0.72% | 94,894 |
24-05-23 | 27,800 | +0.72% | 55,227 |
24-05-22 | 27,600 | +2.41% | 138,222 |
24-05-21 | 26,950 | +2.47% | 92,772 |
24-05-20 | 26,300 | +0.77% | 27,170 |
End-of-day quote Korea S.E., May 23, 2024
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+8.32% | 160M | |
+18.78% | 20.41B | |
0.00% | 19.12B | |
+18.02% | 12.78B | |
-15.06% | 9.11B | |
+27.24% | 8.31B | |
+9.08% | 5.91B | |
-8.58% | 4.15B | |
-17.45% | 3.81B | |
-3.57% | 3.64B |
- Stock Market
- Equities
- A092730 Stock